Your browser doesn't support javascript.
loading
Adjuvant chemotherapy and survival outcomes in older women with HR+/HER2- breast cancer: a propensity score-matched retrospective cohort study using the SEER database.
Ma, Xindi; Wu, Shang; Zhang, Xiangmei; Chen, Nannan; Yang, Chenhui; Yang, Chao; Cao, Miao; Du, Kaiye; Liu, Yunjiang.
Afiliação
  • Ma X; Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Wu S; Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, Hebei, China.
  • Zhang X; Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Chen N; Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, Hebei, China.
  • Yang C; Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, Hebei, China.
  • Yang C; The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Cao M; Department of Pharmacology, Hebei Medical University, Shijiazhuang City, China.
  • Du K; Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Liu Y; Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, Hebei, China.
BMJ Open ; 14(3): e078782, 2024 Mar 15.
Article em En | MEDLINE | ID: mdl-38490656
ABSTRACT

OBJECTIVES:

This study aimed to investigate the impact of adjuvant chemotherapy (ACT) on survival outcomes in older women with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC).

DESIGN:

A retrospective cohort study using data from the Surveillance, Epidemiology, and End Results database, which contains publicly available information from US cancer registries. SETTING AND

PARTICIPANTS:

The study included 45 762 older patients with BC aged over 65 years diagnosed between 2010 and 2015.

METHODS:

Patients were divided into two groups based on age 65-79 years and ≥80 years. Propensity score matching (PSM) was employed to balance clinicopathological characteristics between patients who received ACT and those who did not. Data analysis used the χ2 test and Kaplan-Meier method, with a subgroup analysis conducted to identify potential beneficiaries of ACT. OUTCOME

MEASURES:

Overall survival (OS) and cancer-specific survival (CSS).

RESULTS:

Due to clinicopathological characteristic imbalances between patients with BC aged 65-79 years and those aged ≥80 years, PSM was used to categorise the population into two groups for

analysis:

the 65-79 years age group (n=38 128) and the ≥80 years age group (n=7634). Among patients aged 65-79 years, Kaplan-Meier analysis post-PSM indicated that ACT was effective in improving OS (p<0.05, HR=0.80, 95% CI 0.73 to 0.88), particularly in those with advanced disease stages, but did not show a significant benefit in CSS (p=0.09, HR=1.13, 95% CI 0.98 to 1.31). Conversely, for patients aged ≥80 years, ACT did not demonstrate any improvement in OS (p=0.79, HR=1.04, 95% CI 0.79 to 1.36) or CSS (p=0.09, HR=1.46, 95% CI 0.69 to 2.26) after matching. Subgroup analysis also revealed no positive impact on OS and CSS.

CONCLUSIONS:

Patients with HR+/HER2- BC ≥80 years of age may be considered exempt from ACT because no benefits were found in terms of OS and CSS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Aged / Aged80 / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Aged / Aged80 / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article